WithdrawnPhase 1NCT03196401
A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
Studying Plasmacytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Alexander Lesokhin, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Durvalumab(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2020
Study locations (6)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
- Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
- Memorial Sloan Kettering Commack, Commack, New York, United States
- Memorial Sloan Kettering Westchester, Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States
Collaborators
Celgene Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03196401 on ClinicalTrials.govOther trials for Plasmacytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07115667Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow InfiltrationInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06863584SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II TrialSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE1, PHASE2NCT06429150Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or PlasmacytomaShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT05248633Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary PlasmacytomaPeking Union Medical College Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT04174196A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT04166565Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary DiseaseStichting European Myeloma Network
- ACTIVE NOT RECRUITINGPHASE3NCT02544308Trial of Immunomodulatory Therapy in High Risk Solitary Bone PlasmacytomaUniversity College, London